Cancer Family
Malignant Neoplasm
CI-CAN-00000025CAExplore in graph →
20,108 active trials259 approved drugs3,741 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000025CAExplore in graph →
Clinical trials
90,662 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (11,158)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06395337 | Multimodal Imaging in Rectal Cancer & Pancreatic Cancer(MIRCA & MIPAC) | unknown | Phase 1 / Phase 2 | 20 | Radboud University Medical CenterOTHER | 1 | May 2, 2024 | clinicaltrials |
| NCT06392971 | Deep-sea Fish Oil for Prevention of Acute Radiation-induced Esophagitis | unknown | Phase 2 | 120 | First Affiliated Hospital of Chengdu Medical CollegeOTHER | 1 | May 1, 2024 |
| clinicaltrials |
| NCT06394128 | Cangpo Liujun Prescription on Cancer-related Fatigue in Advanced Colorectal Cancer With Spleen Deficiency and Dampness Excess | unknown | Phase 2 | 48 | First People's Hospital of HangzhouOTHER | 1 | May 1, 2024 | clinicaltrials |
| NCT04622007 | Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART)(KICKSTART) | unknown | Phase 2 | 68 | Effector TherapeuticsINDUSTRY | 3 | Apr 30, 2024 | clinicaltrials |
| NCT06206096 | PD-1 Antibody Plus Bevacizumab and CAPOX as First-line Treatment for RAS-mut MSS mCRC | unknown | Phase 2 | 40 | Chinese PLA General HospitalOTHER | 1 | Apr 30, 2024 | clinicaltrials |
| NCT05458544 | [Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application(LUCIDA) | unknown | Phase 1 / Phase 2 | 26 | FutureChemINDUSTRY | 1 | Apr 29, 2024 | clinicaltrials |
| NCT05579184 | [Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application_2(LUCIDA_2) | unknown | Phase 2 | 20 | FutureChemINDUSTRY | 1 | Apr 29, 2024 | clinicaltrials |
| NCT06385847 | To Assess The Patient Preference for Goserelin Microsphere Versus Goserelin Implant in Patients With Prostate Cancer | unknown | Phase 2 | 60 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Apr 26, 2024 | clinicaltrials |
| NCT04499339 | A Phase I/IIa Clinical Trial to Assess Feasibility, Safety and Antitumor Activity of Autologous SLAMF7 CAR-T Cells in Multiple Myeloma | unknown | Phase 1 / Phase 2 | 38 | Wuerzburg University HospitalOTHER | 3 | Apr 25, 2024 | clinicaltrials |
| NCT04745234 | Mogamulizumab Q4week Dosing in Participants With R/R CTCL | unknown | Phase 2 | 34 | Kyowa Kirin, Inc.INDUSTRY | 5 | Apr 25, 2024 | clinicaltrials |
| NCT06383559 | Safety and Efficacy of XELOX Combined With Sintilimab and Lenvatinib in Advanced AFP-positive Gastric Cancer Patients | unknown | Phase 2 | 39 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 25, 2024 | clinicaltrials |
| NCT06384248 | Phase II Clinical Study of LTC004 in Patients With Advanced Sarcoma | unknown | Phase 1 / Phase 2 | 30 | LetolabINDUSTRY | 0 | Apr 25, 2024 | clinicaltrials |
| NCT04085250 | Study of Nivolumab for Non-Small Cell Lung Cancer (Stage III) Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent Chemoradiation Therapy | unknown | Phase 2 | 264 | Sun Yat-sen UniversityOTHER | 1 | Apr 23, 2024 | clinicaltrials |
| NCT04301557 | PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer | unknown | Phase 2 | 25 | Sun Yat-sen UniversityOTHER | 1 | Apr 23, 2024 | clinicaltrials |
| NCT06189833 | Phase 2 Study Applying MRD Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by ASCT - TAURUS(TAURUS) | unknown | Phase 2 | 200 | Stichting European Myeloma NetworkNETWORK | 5 | Apr 23, 2024 | clinicaltrials |
| NCT04808752 | Almonertinib as First-line Treatment in Patients With EGFR Mutations Positive in Advanced NSCLC With Brain Metastases(ACHIEVE) | unknown | Phase 2 | 63 | Zhejiang Cancer HospitalOTHER | 1 | Apr 22, 2024 | clinicaltrials |
| NCT05695313 | Randomized Study Versus Placebo for the Prevention of Neurotoxicity Induced by Weekly PACLITAXEL(NEUROTAX) | unknown | Phase 2 | 60 | Centre Georges Francois LeclercOTHER | 1 | Apr 22, 2024 | clinicaltrials |
| NCT06078306 | CD19CD22 CAR-T Therapy in Patients With High-Risk B Acute Lymphoblastic Leukemia (B-ALL). | unknown | Phase 2 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Apr 22, 2024 | clinicaltrials |
| NCT03579784 | Biomarker-oriented Study of Durvalumab (MEDI4736) in Combination With Olaparib and Paclitaxel in Gastric Cancer | unknown | Phase 2 | 40 | Do-Youn OhOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT04298008 | AZD6738 Plus Durvalumab in Biliary Tract Cancer | unknown | Phase 2 | 26 | Seoul National University HospitalOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT04298021 | DDR-Umbrella Study of DDR Targeting Agents in Advanced Biliary Tract Cancer | unknown | Phase 2 | 74 | Seoul National University HospitalOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT04371224 | NaliCap (Irinotecan Liposome (Nal-IRI)/Capecitabine) vs. NAPOLI (Nal-IRI/5-FU/LV) ) in Advanced Pancreatic Cancer(NaliCap) | unknown | Phase 2 | 200 | Seoul National University HospitalOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT04447092 | Pembrolizumab Plus Chemotherapy in 1st Line Treatment of Pancreatic Cancer | unknown | Phase 2 | 77 | Seoul National University HospitalOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT04727996 | Phase II Study of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Biliary Tract Cancer(BTC-BGB) | unknown | Phase 2 | 43 | Seoul National University HospitalOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT06375486 | Ivonescimab Combined With HAIC for the Treatment of Unresectable Hepatocellular Carcinoma（uHCC）. | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT06375642 | A Single Arm, Single Centered Phase II Trial on the Combination of Adebrelimab, Surufatinib and Irinotecan Liposome-based HAIC in Advanced iCC | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT00110110 | Combination Chemotherapy and Cyclosporine Followed by Focal Therapy for Bilateral Retinoblastoma | unknown | Phase 2 | 71 | The Hospital for Sick ChildrenOTHER | 4 | Apr 17, 2024 | clinicaltrials |
| NCT05925257 | Digital Health Intervention to Improve Health Care and Outcomes for Breast Cancer Patients | unknown | Phase 2 | 410 | Coordinación de Investigación en Salud, MexicoOTHER_GOV | 1 | Apr 17, 2024 | clinicaltrials |
| NCT05926492 | A Clinical Study of Surufatinib Combined With Chemotherapy as Neoadjuvant Treatment in Osteosarcoma | unknown | Phase 2 | 160 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT06233864 | A Study of the Treatment of Disitamab Vedotin in Patients With Locally Advanced or Metastatic Pancreatic Cancer | unknown | Phase 2 | 63 | Sun Yat-sen UniversityOTHER | 0 | Apr 17, 2024 | clinicaltrials |
| NCT06370065 | Serplulimab Combined With Bevacizumab Biosimilar and HAIC in Advanced Hepatocellular Carcinoma (HCC) Patients | unknown | Phase 2 | 35 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT05659056 | Neoadjuvant Study With Pyrotinib and Trastuzumab and Abraxane in Patients With HER2-enriched Breast Cancer | unknown | Phase 2 | 65 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Apr 16, 2024 | clinicaltrials |
| NCT06125834 | Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Progressive Disease After TKIs or HP Therapy | unknown | Phase 2 | 36 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Apr 16, 2024 | clinicaltrials |
| NCT03700099 | Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Treatment With Docetaxel Followed by Enzalutamide | unknown | Phase 2 | 30 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Apr 15, 2024 | clinicaltrials |
| NCT04600817 | A Study to Evaluate the Efficacy and Safety of TJ107 in Lympopenic Patients With Newly Diagnosed Glioblastoma Who Completed Standard Concurrent Chemoradiotherapy (CCRT) | unknown | Phase 2 | 160 | TJ Biopharma Co., Ltd.INDUSTRY | 2 | Apr 15, 2024 | clinicaltrials |
| NCT04908813 | Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer | unknown | Phase 2 | 150 | Shanghai Henlius BiotechINDUSTRY | 1 | Apr 15, 2024 | clinicaltrials |
| NCT05145907 | Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid Tumors | unknown | Phase 2 | 133 | TJ Biopharma Co., Ltd.INDUSTRY | 1 | Apr 15, 2024 | clinicaltrials |
| NCT06364826 | Sintilimab Combination Therapy Plus IMRT in Nasopharyngeal Carcinoma | unknown | Phase 2 | 60 | Zhejiang Cancer HospitalOTHER | 0 | Apr 15, 2024 | clinicaltrials |
| NCT05240131 | A Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC). | unknown | Phase 1 / Phase 2 | 88 | Galecto Biotech ABINDUSTRY | 3 | Apr 12, 2024 | clinicaltrials |
| NCT06014372 | Envafolimab Monotherapy or Envafolimab + CAPEOX as Neoadjuvant Therapy for Locally Advanced Colorectal Cancer | unknown | Phase 2 | 55 | Sun Yat-sen UniversityOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT06362694 | Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy | unknown | Phase 2 | 10 | Saint Petersburg State University, RussiaOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT06363552 | A Study of SC-0191 in Subjects With Metastatic Colorectal Cancer | unknown | Phase 2 | 36 | Tianshu LiuOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT06364007 | HAIC Combined With Durvalumab and Tremelimumab and Lenvatinib in uHCC | unknown | Phase 2 | 20 | Sulai LiuOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT03639948 | Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer(NeoPACT) | unknown | Phase 2 | 120 | University of Kansas Medical CenterOTHER | 1 | Apr 11, 2024 | clinicaltrials |
| NCT05519293 | Phase I/IIa Study of H002 in NSCLC With Active EGFR Mutation | unknown | Phase 1 / Phase 2 | 76 | RedCloud BioINDUSTRY | 1 | Apr 11, 2024 | clinicaltrials |
| NCT05552781 | H002 in Patients With EGFR Mutation Locally Advanced or Metastatic NSCLC | unknown | Phase 1 / Phase 2 | 76 | RedCloud BioINDUSTRY | 1 | Apr 11, 2024 | clinicaltrials |
| NCT06308406 | A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian Cancer | unknown | Phase 1 / Phase 2 | 54 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 11, 2024 | clinicaltrials |
| NCT04469127 | A Phase I/II Multicenter, Open-Label Study of Lu-177-DOTAGA-IAC, for the Treatment of Angiogenic Breast Cancer Patients.(Heroine01) | unknown | Phase 1 / Phase 2 | 100 | Advanced Imaging Projects, LLCINDUSTRY | 2 | Apr 10, 2024 | clinicaltrials |
Data updated 23 days agoSource updated May 2, 2024source: clinicaltrials